• Caspase-3 Colorimetric Assay Kit: Applied Workflow

  2026-09-04

  Turn apoptosis biology into a practical, plate-based readout with the Caspase-3 Colorimetric Assay Kit, using DEVD-pNA cleavage to quantify relative enzyme activity in cell and tissue lysates. Its rapid 1–2 hour format is especially useful for connecting inflammatory, stress, and neurodegenerative phenotypes to functional caspase signaling without requiring fluorescence instrumentation.

• Firefly Luciferase mRNA Workflow Guide

  2026-09-03

  Build sensitive reporter assays, compare delivery systems, and troubleshoot expression using Cap1- and 5-moU-modified Firefly Luciferase mRNA. The workflow separates transcript performance from carrier effects, making it useful for cell-based screening, formulation development, and exploratory imaging studies.

• DMXAA (Vadimezan) Workflow for Tumor Vascular Studies

  2026-09-03

  Build more informative tumor-vascular assays with DMXAA (Vadimezan) by separating endothelial injury, angiogenesis inhibition, and tumor-cell stress. This practical guide covers formulation, dose finding, orthogonal readouts, model selection, and troubleshooting for cancer biology research.

• Baicalein: From LOX Biology to Assay Design

  2026-09-02

  Baicalein research is strengthened when 12-LOX inhibition, apoptosis, inflammation, and assay controls are interpreted together. This guide connects Baicalein chemistry with a recent neurotoxicity study to support more rigorous experimental design without overstating cross-domain evidence.

• LY2603618: A Practical Chk1 Workflow

  2026-09-02

  LY2603618 is a selective Chk1 inhibitor for mapping checkpoint failure, DNA damage, and abnormal mitotic progression in cancer models. This workflow connects dose-response testing with cell-cycle, phospho-H2AX, microscopy, and chemotherapy-sensitization readouts.

• CDK9 inhibitor (A3294): Protocol and QC Guide

  2026-09-01

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for investigating CDK9-dependent transcription elongation and HIV-1 propagation in controlled research workflows. It is appropriate for targeted CDK9 studies, but not for broad CDK inhibition, conclusions about general cell cycle regulation, or long-term storage of prepared solutions.

• Oligo (dT) 25 Beads: Practical mRNA Guide

  2026-09-01

  Oligo (dT) 25 Beads provide a magnetic workflow for enriching polyadenylated eukaryotic mRNA from total RNA or clarified animal and plant samples. They are not a general RNA purification reagent and should not be used as the sole strategy for non-polyadenylated RNA, most prokaryotic RNA, or severely degraded material lacking usable polyA tails.

• Iptacopan (LNP023) in Complement Research

  2026-08-31

  Iptacopan (LNP023) enables selective, reversible factor B inhibition across serum, red-cell, and disease-model workflows. This guide translates its alternative pathway mechanism into practical assay design, controls, optimization steps, and evidence-aware troubleshooting.

• Reserpine (N1867): Practical Lab Workflow

  2026-08-31

  Reserpine (SKU N1867) provides a characterized research material for neurotransmitter depletion research, neuropharmacology research, and controlled antihypertensive mechanism studies. This guide addresses identity checks, solvent selection, fresh-solution preparation, storage, and QC; the compound is for research use only and is not intended for diagnostic, therapeutic, clinical, or veterinary use.

• Oleic Acid C18:1(9Z): From Lipid Stress to Translation

  2026-08-30

  Oleic Acid is more than a lipid-loading reagent: it is a controllable perturbation for testing how fatty-acid handling shapes cellular injury, signaling, and therapeutic response. This article connects C18:1(9Z) assay design with findings from a hepatic ischemia-reperfusion study and outlines a translational framework for building interpretable lipid metabolism, inflammation, and cancer models.

• Synthetic OLIG2 mRNA Drives Rapid hiPSC OL Differentiation

  2026-08-29

  The reference study developed a transgene-free strategy for converting human induced pluripotent stem cells into oligodendrocyte progenitor cells using repeated delivery of synthetic modified OLIG2 mRNA. A phosphorylation-site mutant, OLIG2S147A, supported rapid generation of NG2-positive progenitors, which matured into functional oligodendrocytes and promoted remyelination in vivo.

• Fluo-4 AM Calcium Assay Kit for Mechanotransduction

  2026-08-28

  The Fluo-4 AM Calcium Assay Kit converts rapid intracellular Ca²⁺ changes into a practical live-cell readout for scaffold mechanobiology and scalable GPCR screening. Its 488 nm excitation, solubility enhancement, and no-wash workflow help connect fiber architecture with cell signaling while preserving throughput and cell viability.

• Dinaciclib and Tissue Boundary Assays

  2026-08-28

  Dinaciclib (SCH727965) links CDK inhibition with experimentally testable changes in proliferation, apoptosis, and epithelial organization. This article develops a mechanobiology-informed assay strategy that extends beyond conventional cell-cycle arrest readouts.

• Iptacopan Monotherapy in PNH: Study Findings

  2026-08-27

  This open-label phase 2 proof-of-concept study tested oral factor B inhibition with Iptacopan (LNP023) as monotherapy in treatment-naive patients with active paroxysmal nocturnal hemoglobinuria. Rapid reductions in lactate dehydrogenase, improvements in hemoglobin and other hemolysis markers, and reduced transfusion requirements support proximal alternative-pathway inhibition as an oral treatment strategy, while the small uncontrolled design limits definitive efficacy and safety conclusions.

• Natural Compounds for COVID-19: Docking Study Insights

  2026-08-27

  The reference study used virtual screening, molecular docking, and molecular dynamics to evaluate vitamin-derived compounds against both the SARS-CoV-2 spike receptor-binding domain and the main protease. Its results identify several candidates with computationally favorable interactions at ACE2-contacting or catalytic residues, while also highlighting the need for biochemical and cellular validation before therapeutic conclusions can be drawn.

8500 records 1/567 page Next 12345 下5页 Last page